GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
NCT06984328 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect82/100
StatusTERMINATED
PhasePHASE2
Lead sponsorGenmab
Last update2026-09-30
Public-record facts
| Intervention | Acasunlimab (BIOLOGICAL), Pembrolizumab (BIOLOGICAL) |
|---|---|
| Condition | Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV) |
| Enrollment | 1 |
| Why stopped | Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns. |
| Results posted | Yes |
Why Beacon surfaced it
- The record is terminated and was updated 2026-09-30.
- It is an interventional PHASE2 study with a named biological/biological intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
- ClinicalTrials.gov indicates posted results are available.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT06984328. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.